

CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications

Eligible Medicare beneficiaries may now get Wegovy, Zepbound or Foundayo for \$50 per month

July 2, 2026 By Centers for Medicare & Medicaid Services

Eligible Medicare beneficiaries may now get certain GLP-1 medications for \$50 per month through the Medicare GLP-1 Bridge, a new Centers for Medicare & Medicaid Services (CMS) initiative designed to expand access to innovative treatments and test the impacts of increased access to GLP-1 drugs for weight management on the Medicare program.

Through the Medicare GLP-1 Bridge, eligible individuals enrolled in Medicare Part D prescription drug coverage can obtain certain GLP-1 medications to lose weight or maintain weight reduction at a predictable and affordable cost of \$50 per month. The initiative will remain available through December 31, 2027, and reflects CMS' continued focus on improving access to innovative treatments that support better long-term health outcomes.

"For too long, many Americans have been unable to access these treatments because of cost," said CMS Administrator Dr. Mehmet Oz. "The Medicare GLP-1 Bridge creates a new pathway for eligible beneficiaries to afford GLP-1 medications. If you think a GLP-1 medication may be right for you, talk with your doctor and learn whether you qualify."

Medicare beneficiaries interested in learning whether they qualify for the Medicare GLP-1 Bridge should visit [Medicare.gov/glp1bridge](https://www.medicare.gov/glp1bridge) and talk with their doctor about whether a GLP-1 medication may be right for them.

Not all Medicare beneficiaries will qualify for the Medicare GLP-1 Bridge, including individuals who already receive GLP-1 medications through their existing Medicare prescription drug coverage or are eligible for GLP-1 coverage through the Medicare Part D benefit.

CMS also has released resources for prescribers and pharmacies to support Medicare GLP-1 Bridge implementation. These materials, along with eligibility information and details about the initiative, are available

at <https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge>.

The Medicare GLP-1 Bridge builds on CMS' broader efforts to improve access to innovative therapies and support healthier outcomes for Medicare beneficiaries.

This [news release](#) was published by the Centers for Medicare & Medicaid Services on July 1, 2026.

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.covidhealth.com/article/cms-launches-medicare-glp1-bridge-expanding-access-glp1-medications>